ନ୍ୟୁଜରୁମ୍ ଓଡ଼ିଶା
ବ୍ରେକିଂ
ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀ

Zydus gets final approval from US FDA for Type 2 diabetes pills

Ahmedabad, July 19 (IANS) Indian pharma company Zydus Lifesciences on Friday said that it has received final approval from the US Food and Drug Administration (USFDA) to market tablets for Type 2 diabetes. The drugmaker said it got “approval for its New Drug Application (NDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets”.

Admin•ଜୁଲାଇ 18, 2024
Share Article:

Ahmedabad, July 19 (IANS) Indian pharma company Zydus Lifesciences on Friday said that it has received final approval from the US Food and Drug Administration (USFDA) to market tablets for Type 2 diabetes.

The drugmaker said it got “approval for its New Drug Application (NDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets”.

With this, Zydus has all three NDAs of Sitagliptin (base) and combination franchise approved, it added.

“Notably, all the three NDAs achieved first-cycle approval (FCA),” the company stated.

Further, it added that the product will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India.

According to IQVIA (MAT May 2024), the US market for DPP-IV inhibitors and its combinations is $9.5 bn.

–IANS

rvt/rad

#health-lifestyle#odisha
Share Article:

Related Articles

ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀ

Study decodes why promising cancer treatments trigger serious side effects

Admin•ଜୁଲାଇ 8, 2025
Study decodes why promising cancer treatments trigger serious side effects
Admin•ଜୁଲାଇ 6, 2025
Covid hospitalisation, family history, lifestyle behaviours behind unexplained sudden death: ICMR study
ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀ

ICMR, AIIMS studies found no link between Covid vaccine & sudden deaths: Centre

Admin•ଜୁଲାଇ 1, 2025
ICMR, AIIMS studies found no link between Covid vaccine & sudden deaths: Centre